Biogen
Executive Summary
Agreement with Mallinckrodt Medical covers the development of nuclear imaging products that can detect blood clots in veins and arteries using Biogen's proprietary antithrombotic drug hirulog. Hirulog is currently in Phase II studies for the prevention and treatment of blood clot diseases.